Patent · US Active

Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands

US8278320B2 · kind B2 · utility

4Cited by

2References

14Claims

0Family size

Assignee

Bristol-Myers Squibb Company · US

Inventors

Ivar M. McDonald · East Haddam, US
Robert A. Mate · Waterbury, US
James H. Cook, II · East Hampton, US
Dalton King · Hamden, US
Richard E. Olson · Wilmington, US
Nenghui Wang · Guilford, US
Christiana I. Iwuagwu · Wallingford, US
F. Christopher Zusi · Williamsville, US
Matthew D. Hill · Wallingford, US
Haiquan Fang · Madison, US
John E. Macor · Guilford, US

Key dates

Filing date	Oct 19, 2010
Grant date	Oct 2, 2012
Priority date	—
Expiry date	Oct 22, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D519/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The disclosure provides compounds of formula I, including Ia, Ib, Ic, or Id, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.